Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.
Brianna C PeacockSanjna TripathyHannah L HananiaHannah Y WangZsila S SadighiAnisha B PatelPublished in: Journal of neuro-oncology (2024)
Improvement in characterization of MEKi toxicities and their management is important to develop treatment guidelines for pediatric and young adult patients with NF1 on MEKi therapy.